Present and Future: Pharmacologic Treatment of Obesity

被引：39

作者：

Glandt, Mariela ^{[1
]}

Raz, Itamar ^{[2
]}

机构：

[1] Bronx Lebanon Hosp Ctr, Dept Endocrinol, Bronx, NY 10457 USA

[2] Univ Med Sch, Ctr Diabet, IL-12000 Jerusalem, Israel

来源：

JOURNAL OF OBESITY | 2011年 / 2011卷

关键词：

D O I：

10.1155/2011/636181

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity now presents one of the biggest health problems of our times. Diet and exercise are best for both prevention and treatment; unfortunately, both require much discipline and are difficult to maintain. Medications offer a possible adjunct, but their effect is modest, they are limited by side effects, and the weight loss lasts only as long as the drug is being taken, since as soon as treatment is stopped, the weight is regained. Sibutramine, a sympathomimetic medication which was available for long-term treatment, is the most recent of the drugs to be withdrawn from the market due to side effects; in this case it was an increased risk of cardiovascular events. This paper reviews those medications which are available for treatment of obesity, including many of those recently taken off the market. It also discusses some of the newer treatments that are currently being investigated.

引用

页数：13

共 115 条

[11] Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease [J].

Astrup, Arne ;

Meier, Dieter H. ;

Mikkelsen, Birgit O. ;

Villumsen, John S. ;

Larsen, Thomas M. .

OBESITY, 2008, 16 (06) :1363-1369

[12] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

[13] Long-term drug treatment of obesity in a private practice setting [J].

Atkinson, RL ;

Blank, RC ;

Schumacher, D ;

Dhurandhar, NV ;

Ritch, DL ;

Levine, J ;

Chan, E ;

Rieg, TS .

OBESITY RESEARCH, 1997, 5 (06) :578-586

[14] Inhibition of food intake in obese subjects by peptide YY3-36 [J].

Batterham, RL ;

Cohen, MA ;

Ellis, SM ;

Le Roux, CW ;

Withers, DJ ;

Frost, GS ;

Ghatei, MA ;

Bloom, SR .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :941-948

[15] 5-HT2C receptor agonists as potential drugs for the treatment of obesity [J].

Bickerdike, MJ .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (08) :885-897

[16] EFFECT OF DEGREE OF WEIGHT-LOSS BENEFITS [J].

BLACKBURN, G .

OBESITY RESEARCH, 1995, 3 :S211-S216

[17] Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes [J].

Blonde, L. ;

Klein, E. J. ;

Han, J. ;

Zhang, B. ;

Mac, S. M. ;

Poon, T. H. ;

Taylor, K. L. ;

Trautmann, M. E. ;

Kim, D. D. ;

Kendall, D. M. .

DIABETES OBESITY & METABOLISM, 2006, 8 (04) :436-447

[18]

Bloomgarden ZT, 2010, DIABETES CARE, V33, pE60, DOI [10.2337/dc10-zb01, 10.2337/dc10-zb09, 10.2337/dc10-zb07, 10.2337/dc10-zb02, 10.2337/dc10-zb08, 10.2337/dc10-zb03, 10.2337/dc10-zb05]

[19] Sibutramine produces dose-related weight loss [J].

Bray, GA ;

Blackburn, GL ;

Ferguson, JM ;

Greenway, FL ;

Jain, AK ;

Mendel, CM ;

Mendels, J ;

Ryan, DH ;

Schwartz, SL ;

Scheinbaum, ML ;

Seaton, TB .

OBESITY RESEARCH, 1999, 7 (02) :189-198

[20] A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity [J].

Bray, GA ;

Hollander, P ;

Klein, S ;

Kushner, R ;

Levy, B ;

Fitchet, M ;

Perry, BH .

OBESITY RESEARCH, 2003, 11 (06) :722-733

← 1 2 3 4 5 6 7 8 9 10 →